SOUTH PLAINFIELD, N.J., Feb. 17, 2011 /PRNewswire/ — Dr.
Abraham Abuchowski, CEO and Scientific Founder of Prolong
Pharmaceuticals, was honored by the U.S. Small Business
Administration on February 15 with their inaugural Tibbetts Award
for leadership in innovation and job creation. Dr. Abuchowski was
one of eight individuals recognized, and the only honoree in the
pharmaceutical/biopharmaceutical industry.
Dr. Abuchowski was the originator of the PEGylation technology,
now the most widely-used protein drug delivery system in the world.
Prior to being one of the founders of Prolong Pharmaceuticals, Dr.
Abuchowski founded Enzon Pharmaceuticals, now a fully integrated,
publicly-traded company. During his time as CEO Enzon successfully
introduced the PEGylation technology and brought three new
protein-based drugs to market with FDA approval. PEGylated drugs
have garnered sales in the tens of billions of dollars around the
world.
The Tibbetts Award winners were honored for the critical role
they play in research and development for the government and for
their success in driving innovation and creating new jobs. “Winning
the future requires redoubling our commitment to supporting
innovative entrepreneurs like those we honor with Tibbetts Awards,”
said Karen Mills, SBA administrator. “Their stories illustrate the
promise of the new generation of innovative entrepreneurs and
remind us all how central the success of one high growth small
business can be to our competitiveness as a nation.”
About Prolong Pharmaceuticals
Headquartered in South Plainfield, New Jersey, Prolong
Pharmaceuticals, LLC is developing biopharmaceutical products
targeting the treatment of anemia resulting from an oxygen
deficiency. First founded in 2002 as a research company, Prolong is
focused on sickle cell anemia, diabetic ischemia, and several
trauma indications. The company’s senior management team includes
inventors of the most successful drug del
‘/>”/>
